Psychiatric Times Editors

We asked our readers if they thought psychiatry is doing enough to address federal doubt. Here's how they responded.

How do your fellow clinicians feel about ethical quandaries in psychiatry? Find out here.

We want to hear from you: what else can psychiatry do to address federal doubt?

Subscribe to our brand new LinkedIn newsletter!

We want to hear from you: what ethical issues in psychiatry are you most worried about?

How do your fellow clinicians feel about the holidays? Are they feeling the effects of burnout heading into 2025? Find out here.

Do you feel burnt out heading into the holidays? Tell us about it!

Would you like to be featured in an upcoming print issue? Submit an article on child & adolescent psychiatry!

The first-in-class muscarinic agonist Cobenfy, formerly known as KarXT, was just approved by the FDA to treat schizophrenia in adults. Are you ready to discuss it with patients and caregivers?

Enter your email to see the results of our polls on social media usage amongst mental health clinicians!

How comfortable do you feel in your knowledge of this type of treatment?

Tell us more about how you use social media as a mental health clinician!

Tell us more about how you use social media as a mental health clinician!

Tell us more about how you use social media!

Here are highlights from the week in Psychiatric Times.

Answer a quick question on psychedelics!

Answer a quick question about psychedelics!

Answer a quick question on psychedelics!

Answer a quick question on psychedelics!

Answer a quick question on psychedelics!

Answer a quick question on psychedelics!

Write to us now for a chance to be featured in our upcoming Special Report on Addiction.

We asked some of the presenters and attendees of the upcoming 2024 APA Annual Meeting what they were excited about. Here's what they said.

Are you coming to the 2024 APA Annual Meeting? We'll see you there!

Let us know if we'll see you there!

Have you checked out the latest Translating Research Into Practice column? Let us know!

What are your top 3 ethics issues? Take our survey!

We're looking for articles with an emphasis on clinical care for marginalized populations...

Biogen announced its decision to discontinue all development and sales of aducanumab (Aduhelm) for Alzheimer disease. Is this surprising?

Take our poll!